For use by Sanofi Medical Afffairs for scientific exchange and medical discussion only. Do not Photograph, copy or distribute.
WELCOME TO the
Yellow FeverQuiz
start
Sanofi does not provide medical advice, diagnosis, or treatment. The information contained herein is provided for general educational purposes only
Hello! As a healthcare professional, you are consulting with a patient who is planning a family trip but is undecided about the destination, between Brazil and Kenya. Your goal is to educate him about Yellow Fever and assist him in making an informed decision.
New Player
Please answer the following 6 questions plus a survey question if you take it. Once you submit your choice, you cannot go back and change it.
"New Player" button will start a new game and will reset your progress, allowing you to enter a new pseudo.
You can click this button anytime to check your score
And now, let's start!
Play
For use by Sanofi Medical Afffairs for scientific exchange and medical discussion only. Do not Photograph, copy or distribute.
1. Destination dilemna
New Player
For use by Sanofi Medical Afffairs for scientific exchange and medical discussion only. Do not Photograph, copy or distribute.
1. Destination dilemna
In November 2022, the World Health Organization claimed that 42 countries are at-risk of Yellow Fever transmission1, 29 in Africa and 13 in Central and South America. Yellow Fever is an acute viral disease transmitted by infected mosquitoes. Countries where there is a "risk of Yellow Fever transmission", as defined by WHO, are countries or areas where "Yellow Fever is currently or has been reported, and where vectors and animal reservoirs currently exist".
New Player
World Health Organization (WHO) Nov 2022. Countries With Risk Of Yellow Fever Transmission And Countries Requiring Yellow Fever Vaccination. 18 November 2022 Available At: Countries with risk of yellow fever transmission and countries requiring yellow fever vaccination (November 2022) (who.int)
Next
For use by Sanofi Medical Afffairs for scientific exchange and medical discussion only. Do not Photograph, copy or distribute.
2. Disease severity
New Player
The patient asks whether Yellow Fever may be a serious and deadly disease.
For use by Sanofi Medical Afffairs for scientific exchange and medical discussion only. Do not Photograph, copy or distribute.
2. Disease severity
For use by medical for scientific exchange and medical discussions only. Do not Photograph, copy or distribute.
False!
New Player
Around 12 to 15 % of Yellow Fever cases progress to severe forms and approximately 20-60% of severe cases result in death1,2 It is estimated that Yellow Fever causes around 109, 000 (95% CI: 67,000–173,000) severe infections and 51, 000 (95% CI: 31,000–82,000) deaths every year4. The true number of Yellow Fever cases could be much higher (underreporting and asymptomatic/mild cases)2,5
- Johansson MA, et al. The whole iceberg: estimating the incidence of yellow fever virus infection from the number of severe cases. Trans R Soc Trop Med Hyg. 2014 Aug;108(8):482-7.
- World Health Organization (WHO). Yellow Fever Fact Sheet. 7 May 2019 Available at https://www.who.int/en/news-room/fact-sheets/detail/yellow-fever
- Monath TP & Vasconcelos PF. Yellow Fever. J clin Virol 2015 at https://www.sciencedirect.com/science/article/pii/S1386653214003692?via%3Dihub
- Gaythorpe KA, et al. The global burden of yellow fever. Elife. 2021 Mar 16;10:e64670. Available at: The global burden of yellow fever | eLife (elifesciences.org)
- CDC: Yellow Fever Vaccine: Recommendations of the Advisory Committee on Immunization Practices MMWR Morb Mortal Wkly Rep. 2010; 59(RR07): 1-27
Next
3. Vaccine indication
New Player
The patient wonders about vaccine administration for himself and his family (wife, 6-month-old baby and 74-year-old parents):
For use by Sanofi Medical Affairs for scientific exchange and medical discussions only. Do not Photograph, copy or distribute.
3. Vaccine indication
NO! Yellow Fever vaccination is not indicated in infants below 9 months of age. It is indicated for individuals from 9 months of age traveling to or living in areas with risk for Yellow Fever virus transmission.1-2 The Yellow Fever vaccine should be used with caution in persons over 60 years due to a potentially higher risk of severe Yellow Fever vaccine-associated diseases (Yellow Fever Vaccine-Associated Neurotropic Disease [YEL-AND] and Yellow Fever Vaccine-Associated Viscerotropic Disease [YEL-AVD]). In these individuals, Yellow Fever Vaccination may be considered following careful evaluation of the risks and benefits.2-3
New Player
- US-CDC yellow fever vaccine. available at: https://www.cdc.gov/yellow-fever/vaccine/index.html [accessed February 2025]
- WHO- Position paper on Yellow Fever vaccine. 2013 N°27: 269-283
- Khromava A et al. Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events. Vaccine (2005). 23: 3256-63
Next
For use by Sanofi Medical Affairs for scientific exchange and medical discussions only. Do not Photograph, copy or distribute.
4. Duration of vaccine protection
The patient may go on other trips with his family in the future. He wonders if he will have to repeat vaccination against Yellow Fever.
New Player
For use by Sanofi Medical Affairs for scientific exchange and medical discussions only. Do not Photograph, copy or distribute.
4. Duration of vaccine protection
LIFE-LONG! For most people, a single dose of Yellow Fever vaccine provides long-lasting protection, and a booster dose of the vaccine is not needed.1-2 The validity of the International certificate of vaccination against Yellow Fever is for lifetime, beginning 10 days after the date of Yellow Fever vaccination.2
New Player
Re-vaccination with 1 dose may be needed under specific circumstances, e.g., in subjects with an insufficient immune response to primary vaccination, or depending on official recommendations of local health authorities.3 Note: recommendations for Yellow Fever vaccination and booster may differ according to the country. Please refer to your local regulations.
- US-CDC yellow fever vaccine. available at: https://www.cdc.gov/yellow-fever/vaccine/index.html [accessed February 2025]
- WHO- Lifetime validity of one dose of Yellow fever vaccine. Available at: https://www.who.int/publications/m/item/lifetime-validity-of-one-dose-of-yellow-fever-vaccine [accessed February 2025]
- Staples JE et al 2015 MMWR 64(23):647-50
Next
For use by Sanofi Medical Affairs for scientific exchange and medical discussions only. Do not Photograph, copy or distribute.
5. Recommendations for at-risk of transmission countries
New Player
The patient asks:
For use by Sanofi Medical Affairs for scientific exchange and medical discussions only. Do not Photograph, copy or distribute.
5. Recommendations for at-risk of transmission countries
NO! Several countries determined by WHO to be at risk for Yellow Fever transmission do not require proof of vaccination for all travellers. This is often the case when the risk of Yellow Fever transmission is present only in parts of the country (e.g. Brazil, Kenya, Peru). The risk of being exposed to Yellow Fever should be assessed depending on the destination to evaluate the need for vaccination.1-2
New Player
- World Health Organization (WHO) Nov 2022. Countries With Risk Of Yellow Fever Transmission And Countries Requiring Yellow Fever Vaccination. 18 November 2022 Available At: Countries with risk of yellow fever transmission and countries requiring yellow fever vaccination (November 2022) (who.int) [accessed February 2025]
- World Health Organization (WHO) Nov 2022 - INTERNATIONAL TRAVEL AND HEALTH COUNTRY LIST– 18 NOVEMBER 2022 (REVISED ON 3 JANUARY 2023). available at: https://www.who.int/publications/m/item/vaccination-requirements-and-recommendations-for-international-travellers-and-malaria-situation-per-country-2022-edition [accessed February 2025]
Next
For use by Sanofi Medical Affairs for scientific exchange and medical discussions only. Do not Photograph, copy or distribute.
6. Impact of vector range
New Player
After seeing the list of countries at risk for Yellow Fever, the patient is reassured to know that the virus is not circulating in the US.
For use by Sanofi Medical Affairs for scientific exchange and medical discussions only. Do not Photograph, copy or distribute.
6. Impact of vector range
YES! Yellow Fever epidemics appeared in the U.S. in the late 17th century. The last significant Yellow Fever outbreak occurred in New Orleans in 1905.1 Vector control and vaccination have helped eliminate the disease in the U.S. Aedes aegypti , the mosquito primarily responsible for Yellow Fever virus transmission in urban settings, is expected to spread mainly within tropical areas and new temperate regions, reaching as far north as Chicago and Shanghai.2 About half the world’s population could be exposed to Aedes aegypti mosquitoes and potentially to virus transmission including Yellow Fever, Zika and Dengue viruses.2 Climate change, globalization, continuous population growth, and urbanization associated with inadequate public health infrastructure constitute important promoting factors for the spread of Yellow Fever virus to mosquito-infested regions capable of spreading the disease.3 Climate change may also have substantial effects on the transmission of Yellow Fever in already endemic areas4.
New Player
- Prinzi A. History of Yellow Fever in the U.S. Amercan Society for Microbiology. 2021. available in: https://asm.org/articles/2021/may/history-of-yellow-fever-in-the-u-s [accessed feb 2025]
- Kraemer MUG, et al. Past and future spread of the arbovirus vectors Aedes aegypti and Aedes albopictus. Nat Microbiol. 2019 May;4(5):854-863.Kraemer MUG, et al. Nat Microbiol. 2019; 4(5):854-863
- Gianchecchi E, et al. Yellow Fever: Origin, Epidemiology, Preventive Strategies and Future Prospects. Vaccines (Basel). 2022 Feb 27;10(3):372.
- Gaythorpe K, et al. (2020) The effect of climate change on yellow fever disease burden in Africa eLife 9:e55619. The effect of climate change on yellow fever disease burden in Africa | eLife (elifesciences.org)
Next
For use by Sanofi Medical Affairs for scientific exchange and medical discussions only. Do not Photograph, copy or distribute.
Congratulations!
New Player
Great Job!! You have completed the quiz!
Thank you to take the quick survey hereafter (1 sec)
For use by Sanofi Medical Affairs for scientific exchange and medical discussions only. Do not Photograph, copy or distribute. Free characters images by Vecteezy Eezy, LLC 2413 NASHVILLE RD STE B13 BOWLING GREEN, KY, 42101-4136, US. Congratulations jingle is from PIXABAY. MAT-US-2501582 P EXP 20 FEB 2027
Survey
New Player
THANK YOU!
For your participation
Copyright 2025 Sanofi. All rights
reserved.
For use by Sanofi Medical Affairs for scientific exchange and medical discussions only. Do not Photograph, copy or distribute. Free characters images by Vecteezy Eezy, LLC 2413 NASHVILLE RD STE B13 BOWLING GREEN, KY, 42101-4136, US MAT-US-2501582 P EXP 20 FEB 2027
YF QUIZ- US version
medical content
Created on February 17, 2025
Start designing with a free template
Discover more than 1500 professional designs like these:
View
Chaotic Chef Quiz
View
Robotics quiz
View
Superheroes Quiz
View
True or false quiz
View
Essential quiz mobile
View
Professional quiz mobile
View
Corporate Training Quiz
Explore all templates
Transcript
For use by Sanofi Medical Afffairs for scientific exchange and medical discussion only. Do not Photograph, copy or distribute.
WELCOME TO the
Yellow FeverQuiz
start
Sanofi does not provide medical advice, diagnosis, or treatment. The information contained herein is provided for general educational purposes only
Hello! As a healthcare professional, you are consulting with a patient who is planning a family trip but is undecided about the destination, between Brazil and Kenya. Your goal is to educate him about Yellow Fever and assist him in making an informed decision.
New Player
Please answer the following 6 questions plus a survey question if you take it. Once you submit your choice, you cannot go back and change it.
"New Player" button will start a new game and will reset your progress, allowing you to enter a new pseudo.
You can click this button anytime to check your score
And now, let's start!
Play
For use by Sanofi Medical Afffairs for scientific exchange and medical discussion only. Do not Photograph, copy or distribute.
1. Destination dilemna
New Player
For use by Sanofi Medical Afffairs for scientific exchange and medical discussion only. Do not Photograph, copy or distribute.
1. Destination dilemna
In November 2022, the World Health Organization claimed that 42 countries are at-risk of Yellow Fever transmission1, 29 in Africa and 13 in Central and South America. Yellow Fever is an acute viral disease transmitted by infected mosquitoes. Countries where there is a "risk of Yellow Fever transmission", as defined by WHO, are countries or areas where "Yellow Fever is currently or has been reported, and where vectors and animal reservoirs currently exist".
New Player
World Health Organization (WHO) Nov 2022. Countries With Risk Of Yellow Fever Transmission And Countries Requiring Yellow Fever Vaccination. 18 November 2022 Available At: Countries with risk of yellow fever transmission and countries requiring yellow fever vaccination (November 2022) (who.int)
Next
For use by Sanofi Medical Afffairs for scientific exchange and medical discussion only. Do not Photograph, copy or distribute.
2. Disease severity
New Player
The patient asks whether Yellow Fever may be a serious and deadly disease.
For use by Sanofi Medical Afffairs for scientific exchange and medical discussion only. Do not Photograph, copy or distribute.
2. Disease severity
For use by medical for scientific exchange and medical discussions only. Do not Photograph, copy or distribute.
False!
New Player
Around 12 to 15 % of Yellow Fever cases progress to severe forms and approximately 20-60% of severe cases result in death1,2 It is estimated that Yellow Fever causes around 109, 000 (95% CI: 67,000–173,000) severe infections and 51, 000 (95% CI: 31,000–82,000) deaths every year4. The true number of Yellow Fever cases could be much higher (underreporting and asymptomatic/mild cases)2,5
Next
3. Vaccine indication
New Player
The patient wonders about vaccine administration for himself and his family (wife, 6-month-old baby and 74-year-old parents):
For use by Sanofi Medical Affairs for scientific exchange and medical discussions only. Do not Photograph, copy or distribute.
3. Vaccine indication
NO! Yellow Fever vaccination is not indicated in infants below 9 months of age. It is indicated for individuals from 9 months of age traveling to or living in areas with risk for Yellow Fever virus transmission.1-2 The Yellow Fever vaccine should be used with caution in persons over 60 years due to a potentially higher risk of severe Yellow Fever vaccine-associated diseases (Yellow Fever Vaccine-Associated Neurotropic Disease [YEL-AND] and Yellow Fever Vaccine-Associated Viscerotropic Disease [YEL-AVD]). In these individuals, Yellow Fever Vaccination may be considered following careful evaluation of the risks and benefits.2-3
New Player
Next
For use by Sanofi Medical Affairs for scientific exchange and medical discussions only. Do not Photograph, copy or distribute.
4. Duration of vaccine protection
The patient may go on other trips with his family in the future. He wonders if he will have to repeat vaccination against Yellow Fever.
New Player
For use by Sanofi Medical Affairs for scientific exchange and medical discussions only. Do not Photograph, copy or distribute.
4. Duration of vaccine protection
LIFE-LONG! For most people, a single dose of Yellow Fever vaccine provides long-lasting protection, and a booster dose of the vaccine is not needed.1-2 The validity of the International certificate of vaccination against Yellow Fever is for lifetime, beginning 10 days after the date of Yellow Fever vaccination.2
New Player
Re-vaccination with 1 dose may be needed under specific circumstances, e.g., in subjects with an insufficient immune response to primary vaccination, or depending on official recommendations of local health authorities.3 Note: recommendations for Yellow Fever vaccination and booster may differ according to the country. Please refer to your local regulations.
Next
For use by Sanofi Medical Affairs for scientific exchange and medical discussions only. Do not Photograph, copy or distribute.
5. Recommendations for at-risk of transmission countries
New Player
The patient asks:
For use by Sanofi Medical Affairs for scientific exchange and medical discussions only. Do not Photograph, copy or distribute.
5. Recommendations for at-risk of transmission countries
NO! Several countries determined by WHO to be at risk for Yellow Fever transmission do not require proof of vaccination for all travellers. This is often the case when the risk of Yellow Fever transmission is present only in parts of the country (e.g. Brazil, Kenya, Peru). The risk of being exposed to Yellow Fever should be assessed depending on the destination to evaluate the need for vaccination.1-2
New Player
Next
For use by Sanofi Medical Affairs for scientific exchange and medical discussions only. Do not Photograph, copy or distribute.
6. Impact of vector range
New Player
After seeing the list of countries at risk for Yellow Fever, the patient is reassured to know that the virus is not circulating in the US.
For use by Sanofi Medical Affairs for scientific exchange and medical discussions only. Do not Photograph, copy or distribute.
6. Impact of vector range
YES! Yellow Fever epidemics appeared in the U.S. in the late 17th century. The last significant Yellow Fever outbreak occurred in New Orleans in 1905.1 Vector control and vaccination have helped eliminate the disease in the U.S. Aedes aegypti , the mosquito primarily responsible for Yellow Fever virus transmission in urban settings, is expected to spread mainly within tropical areas and new temperate regions, reaching as far north as Chicago and Shanghai.2 About half the world’s population could be exposed to Aedes aegypti mosquitoes and potentially to virus transmission including Yellow Fever, Zika and Dengue viruses.2 Climate change, globalization, continuous population growth, and urbanization associated with inadequate public health infrastructure constitute important promoting factors for the spread of Yellow Fever virus to mosquito-infested regions capable of spreading the disease.3 Climate change may also have substantial effects on the transmission of Yellow Fever in already endemic areas4.
New Player
Next
For use by Sanofi Medical Affairs for scientific exchange and medical discussions only. Do not Photograph, copy or distribute.
Congratulations!
New Player
Great Job!! You have completed the quiz!
Thank you to take the quick survey hereafter (1 sec)
For use by Sanofi Medical Affairs for scientific exchange and medical discussions only. Do not Photograph, copy or distribute. Free characters images by Vecteezy Eezy, LLC 2413 NASHVILLE RD STE B13 BOWLING GREEN, KY, 42101-4136, US. Congratulations jingle is from PIXABAY. MAT-US-2501582 P EXP 20 FEB 2027
Survey
New Player
THANK YOU!
For your participation
Copyright 2025 Sanofi. All rights reserved.
For use by Sanofi Medical Affairs for scientific exchange and medical discussions only. Do not Photograph, copy or distribute. Free characters images by Vecteezy Eezy, LLC 2413 NASHVILLE RD STE B13 BOWLING GREEN, KY, 42101-4136, US MAT-US-2501582 P EXP 20 FEB 2027